Isoproterenol

Mechanism of Action

Isoproterenol is a nonselective beta-1 and beta-2 adrenergic receptor agonist that produces the following effects: 

• Increased heart rate 
• Increased heart contractility 
• Relaxation of bronchial, gastrointestinal, and uterine smooth muscle 
• Peripheral vasodilation 

Both beta-1 and beta-2 adrenergic receptors exert their effects through a G-alpha stimulatory second messenger system. G-protein–coupled receptors are structurally composed of a 7-transmembrane-spanning protein. The extracellular domain serves as the ligand-binding site, whereas the intracellular domain links to a G-alpha stimulatory protein bound to a GDP molecule in the inactivated state.

Upon binding of the ligand to the extracellular domain of a beta-1 receptor, the G-alpha subunit exchanges a GDP molecule for a GTP and becomes activated. The activated G-alpha protein then dissociates from the intracellular domain and activates adenylate cyclase. Activated adenylate cyclase subsequently converts intracellular ATP into cyclic AMP (cAMP), which is the principal second messenger in this pathway.

cAMP activates protein kinase A (PKA), which phosphorylates L-type calcium channels in cardiac myocytes, resulting in increased intracellular calcium. PKA also causes an increase in calcium release from ryanodine receptors on the sarcoplasmic reticulum.

Beta-1 adrenergic receptors are primarily concentrated in cardiac tissues. The terminal effects of beta-1 adrenergic receptor activation are an increase in intracellular calcium. In cardiac pacemaker cells, increased calcium increases the slope of phase 4 of the cardiac pacemaker action potential. By increasing the slope of phase 4, pacemaker cells reach the threshold more rapidly, resulting in the characteristic increase in heart rate observed in patients receiving an isoproterenol infusion. In non-pacemaker cardiac myocytes, an increase in intracellular calcium causes the increased contractility characteristic of isoproterenol infusion.[15]

The result of beta-1 agonism on the heart can be summarized as follows:

• Positive inotropy (contractility)
• Positive lusitropy (relaxation)
• Positive chronotropy (heart rate)
• Positive dromotropy (conduction velocity) 

Beta-2 adrenergic receptors function similarly to beta-1 receptors. Activation of these G-protein–coupled receptors results in an increase in intracellular cAMP, which then activates PKA. PKA phosphorylates and inactivates myosin light chain kinase (MLCK). In smooth muscle cells, MLCK catalyzes myosin phosphorylation, leading to myosin-actin cross-bridge formation and muscle contraction. As stated, agonism of beta-2 receptors leads to inactivation of MLCK and subsequent relaxation of smooth muscle, bronchial dilation, peripheral vasodilation, and relaxation of gastrointestinal and uterine smooth muscle.[16]

Other effects of isoproterenol include:

• Hepatic glycogenolysis via beta-2 adrenergic receptor activation
• Release of glucagon from the pancreas via beta-2 adrenergic receptors
• Activation of the renin-angiotensin-aldosterone system in the kidney through beta-1 adrenergic receptor stimulation [17]

Pharmacokinetics (Adapted From the Label and PubChem)

Absorption: Isoproterenol becomes active immediately upon infusion. 

Distribution: Isoproterenol exhibits approximately 68.8% plasma protein binding. 

Metabolism: Isoproterenol undergoes hepatic metabolism mediated by the cytochrome P450 (CYP450) enzyme system and is also metabolized in other tissues by catechol-O-methyltransferase (COMT).[18] Conjugation in hepatic and pulmonary tissues is the primary metabolic pathway.

Excretion: The elimination half-life of intravenous isoproterenol ranges from 2.5 to 5 minutes. After 48 hours, approximately 12.2% to 27.0% of the drug is recovered in the feces and 59.1% to 106.8% in the urine.

Administration

Isoproterenol is administered intravenously via an infusion pump. Notably, adult intravenous infusion is expressed as micrograms per minute (mcg/min), whereas pediatric dosing is expressed in micrograms per kilogram per minute (mcg/kg/min).

Available Dosage Forms and Strengths

Brand and generic formulations: 0.2 mg/mL solution (1 mL and 5mL) 

Adult Dosage (FDA-Approved)

• Distributive shock and shock due to reduced cardiac output: For preparation, 5 mL (1 mg) of isoproterenol should be diluted in 500 mL of 5% dextrose injection. The recommended adult dose is administered as a continuous intravenous infusion at a rate of 0.5 to 5 mcg/min, which corresponds to 0.25 to 2.5 mL/min of the diluted solution. The infusion rate should be titrated according to heart rate, central venous pressure, blood pressure, and urine output. If the heart rate exceeds 110 beats per minute, dose reduction or temporary discontinuation of the infusion should be considered.

• Bronchospasm during anesthesia: For preparation, 1 mL (0.2 mg) of isoproterenol should be diluted with 10 mL of normal saline or 5% dextrose injection. The initial dose is 10 to 20 mcg, administered as an intravenous bolus, which corresponds to 0.5 to 1 mL of the diluted solution. Subsequent doses equal to the initial dose may be repeated as needed.

• Bradydysrhythmias and AV nodal block: Isoproterenol may be administered as a continuous infusion at a rate of 2 to 10 mcg/min, titrated to the desired clinical effect.[4] 

• Adam-Stokes attacks: For the management of Adams–Stokes attacks, isoproterenol is administered intravenously at a rate of 2 to 20 mcg/min. Therapy should be initiated at 5 mcg/min and adjusted based on clinical response.

Adult Dosage (Off-Label)

• Brugada syndrome: Isoproterenol may be administered as a bolus of 1 to 2 mcg, followed by a continuous infusion at 0.15 to 0.3 mcg/min for up to 24 hours.[9]

• Cardiogenic shock: Isoproterenol may be administered as a continuous infusion at a rate of 2 to 20 mcg/min, titrated to clinical response.[5]

• Provocation of syncope during tilt table testing: Isoproterenol may be initiated at 1 mcg/min and then increased based on the desired physiological response, to a maximum dose of 5 mcg/min.

• Provocation of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy: Isoproterenol may be administered at 45 mcg/min for 3 minutes, followed by rhythm evaluation.[6]

• Refractory torsades de pointes: Isoproterenol may be administered as a continuous infusion at 2 to 10 mcg/min, titrated to patient response.[8] 

Pediatric Dosage

• Bradycardia and AV nodal block: Isoproterenol may be administered as a continuous intravenous infusion at a rate of 0.05 to 0.5 mcg/kg/min, titrated to the desired clinical effect. The maximum recommended dose is 2 mcg/kg/min.[4] 

Neonatal Dosage

• Bradycardia: Isoproterenol may be administered as a continuous infusion at a rate of 0.05 to 1 mcg/kg/min, titrated to clinical effect.[19]

Specific Patient Populations

Hepatic impairment: No dosage adjustment for isoproterenol is specified in the product label for patients with hepatic impairment.

Renal impairment: No dosage adjustment for isoproterenol is specified in the product label for patients with renal impairment.

Pregnancy considerations: The use of isoproterenol during pregnancy has not been specifically evaluated. However, extensive clinical experience with isoproterenol in pregnant patients over several decades has not demonstrated an increased risk of major congenital disabilities, miscarriage, or adverse maternal or fetal outcomes.

Potential risks to both the mother and fetus exist when isoproterenol is administered during labor or delivery. Hypotension due to shock constitutes a medical emergency in pregnancy and may be fatal if not promptly treated. Delays in intervention for shock-related hypotension can increase maternal and fetal morbidity and mortality. Life-sustaining therapy should not be withheld from a pregnant patient because of concerns regarding the potential fetal effects of isoproterenol.

Isoproterenol inhibits spontaneous and oxytocin-induced uterine contractions and may prolong the second stage of labor. Accordingly, its use should be avoided during the second stage of labor. In obstetric practice, isoproterenol should also be avoided when maternal blood pressure exceeds 130/80 mm Hg.

Breastfeeding considerations: The presence of isoproterenol in human breast milk is presently unknown.[20] However, given its short elimination half-life, exposure to a breastfed infant is expected to be minimal.

Pediatric patients: The safety and efficacy of isoproterenol have not been established in pediatrics. Intravenous infusions of isoproterenol in refractory asthma at rates of 0.05 to 2.7 mcg/kg/min have been associated with clinical deterioration, myocardial necrosis, congestive heart failure, and mortality.[21] The risks of cardiac toxicity appear to be increased by acidosis, hypoxemia, and coadministration of corticosteroids, methylxanthines, theophylline, or aminophyllin, which are especially likely to be present in these patients.[22] If isoproterenol is used in pediatric patients with refractory asthma, close monitoring is necessary, including ongoing assessment of vital signs, regular electrocardiographic (ECG) monitoring, and measurement of cardiac enzyme levels.[13]

Older patients: In clinical trials of isoproterenol, the number of enrolled patients aged 65 or older was insufficient to determine whether responses differ from those observed in younger adults. Limited data suggest that healthy or hypertensive older adults are less responsive to beta-adrenergic stimulation than younger subjects. For geriatric patients, dosing should be approached cautiously, typically beginning at the lower end of the dosing range, due to the increased likelihood of reduced hepatic, renal, or cardiac function, as well as the presence of comorbid conditions and concomitant polypharmacy.

Adverse Effects

Adverse effects of isoproterenol may involve multiple organ systems, as mentioned below.

Common

• Headache
• Dizziness
• Upset stomach
• Flushing
• Fatigue
• Nervousness
• Diaphoresis
• Blurred vision
• Tachyarrhythmia
• Hypertension or hypotension

Cardiovascular

• Angina 
• Flushing 
• Hypotension 
• Hypertension 
• Palpitations 
• Ventricular arrhythmia 
• Premature ventricular contractions 
• Adams-stokes syndrome 
• Bradycardia (with tilt table testing) 
• Atrial fibrillation [23]

Respiratory 

• Dyspnea 
• Edema 

Ophthalmic 

• Blurred vision 

Central Nervous System

• Headache
• Dizziness
• Nervousness
• Restlessness
• Seizures 

Gastrointestinal

• Nausea
• Vomiting 

Endocrine and Metabolic

• Hypokalemia
• Increased serum glucose 

Musculoskeletal 

• Tremor
• Weakness 

Drug-Drug Interactions

Risk C: Monitoring therapy

• Atomoxetine: Concomitant use may increase heart rate.
• Cannabinoid-containing products: Concomitant use may increase heart rate.
• Catechol-O-methyltransferase inhibitors: Isoproterenol is degraded by COMT; concomitant use with COMT inhibitors may increase isoproterenol concentrations and the risk of adverse effects.
• Doxofylline: Concomitant use may increase the risk of doxofylline toxicity.
• Tedizolid: Concomitant use may increase the risk of hypertensive episodes.

Risk D: Considering modifying therapy

• Topical cocaine: Concomitant use increases the risk of hypertension, tachycardia, and increased oxygen demand.
• Linezolid: Concomitant use may increase the risk of hypertension due to the COMT inhibitor-like activity of linezolid.
• Mifepristone: Concomitant use may increase the risk of QTc prolongation.
• QTc-prolonging agents: Concomitant administration with other QTc-prolonging drugs should be avoided.
• Epinephrine: Both medications are direct stimulants, and their combined effects may precipitate severe arrhythmias when administered concurrently.
• Beta blockers: Beta-adrenergic blocking drugs, such as propranolol, may antagonize the cardiostimulating and bronchodilating effects of isoproterenol.

Risk X: Avoiding combination or using alternatives

• Inhaled anesthetics: Concomitant use may increase the risk of arrhythmias.
• Benzphetamine
• Clomipramine
• Diethylpropion
• Epinephrine
• Methamphetamine
• Midodrine
• Phendimetrazine
• Procarbazine
• Sotalol

Contraindications

Absolute contraindications include:

• Angina
• Tachydysrhythmias
• Preexisting ventricular arrhythmias
• Digoxin intoxication
• Sulfa allergy (formulations contain sulfites)

Isoproterenol should be used with caution in patients with conditions mentioned below.

• Cardiovascular disease: Isoproterenol increases myocardial oxygen demand.
• Diabetes: Isoproterenol may increase blood glucose levels.
• Distributive shock: Beta-2 adrenergic agonism may further decrease total peripheral resistance.
• Hyperthyroidism: Isoproterenol may induce a thyroid storm.
• Sulfite sensitivity: Formulations contain sulfites, which may provoke allergic reactions in susceptible patients.
• Older patient populations

Monitoring

Clinicians should monitor baseline and periodic electrolyte levels, blood pressure, and an ECG. Vital signs, including heart rate and respiratory rate, along with arterial blood gas analysis, blood glucose levels, and serum potassium and magnesium levels, require continuous monitoring in patients receiving isoproterenol.

Toxicity

Signs and Symptoms of Overdose

Acute toxicity from isoproterenol can cause a significant decrease in blood pressure. Accidental overdose is most commonly manifested by tachycardia or other arrhythmias, hypotension or hypertension, and angina. In such cases, the rate of isoproterenol administration should be reduced or the drug discontinued until the patient stabilizes. Continuous monitoring of pulse, respiratory rate, electrocardiography, and blood pressure is recommended.

Management of Overdose

No known antidote exists for isoproterenol toxicity, although investigational therapies are under study.[24] Management is primarily supportive. Recent animal research indicates that, in isoproterenol-induced heart failure, empagliflozin and sacubitril/valsartan might offer cardioprotective effects and could serve as potential treatment options. Nonetheless, definitive conclusions require larger, evidence-based studies in humans.[25]

Enhancing Healthcare Team Outcomes

Isoproterenol is most commonly prescribed by a cardiologist; however, its use requires close coordination among an interprofessional healthcare team. This team typically includes intensivists, cardiologists, cardiac surgeons, critical care specialists, pharmacists, and ICU nursing staff. Isoproterenol is administered exclusively as an intravenous infusion and is generally reserved for severe bradycardia, heart block, or cardiac arrest. In select circumstances, it may also be used to manage hypovolemic shock or bronchospasm. Due to its potent beta-adrenergic effects, isoproterenol can precipitate tachyarrhythmias and hypertension, particularly at higher doses. When administered in the ICU setting, continuous hemodynamic and electrocardiographic monitoring is required for patients. With the widespread availability of pacemakers and alternative chronotropic agents, the clinical use of isoproterenol has declined in the current medical paradigm.[26]

Effective and safe use of isoproterenol depends on interprofessional collaboration among healthcare providers. While the ordering clinician determines the indication and initiates therapy, optimal management requires active involvement from the entire care team. Pharmacists play a critical role in verifying dosing, preparing infusions, and conducting thorough medication reconciliation. Consultation with a board-certified cardiology pharmacist is particularly valuable, given their expertise in cardiovascular pharmacotherapy, drug interactions, dose adjustments, and monitoring for adverse effects.

Nursing staff are on the front line of obtaining accurate medication histories and performing the ongoing monitoring required during isoproterenol administration. Any abnormal findings or clinical concerns should be promptly communicated to the healthcare team, including prescribing clinicians and pharmacists, to allow timely dose adjustments or therapy modifications. This level of coordination is essential given the severity of the conditions treated with isoproterenol and the potential for significant adverse effects or drug interactions. Nursing staff with specialized training in cardiology or critical care can provide additional clinical insight and enhance patient safety. Effective, collaborative interprofessional communication is essential to optimize isoproterenol therapy, improve clinical outcomes, and minimize adverse events.